Share repurchase programme Noerresundby, Denmark, 8

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
15
Share repurchase programme

Noerresundby, Denmark, 8 February 2019 Announcement no. 10/2019

 

The Board of Directors of RTX has, cf. company announcement no. 03 dated 24. January 2019, resolved to initiate a share buy-back programme in accordance with the provisions of Article 5 Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 (MAR) and the Commission’s delegated Regulation (EU) 2016/1052 of 8 March 2016, also referred to as the "Safe Harbor" rules.

Under the programme RTX will buy back shares for an amount up to DKK 20 million in the period from 25 January 2019 to 30 June 2019.

The following transactions have been made under the programme in the period from 1 February 2019 to 7 February 2019:

  Number of shares Average purchase price Transaction value in DKK
Accumulated, latest announcement   5,100   170.21   868,068
1. February 2019   1,100   169.73   186,703
4. February 2019   1,200   167.18   200,616
5. February 2019   1,300   166.99   217,087
6. February 2019   1,300   167.31   217,503
7. February 2019   1,300   167.43   217,659
Accumulated under the programme   11,300   168.82   1,907,636

With the transactions stated above, RTX A/S owns a total of 322,700 of treasury shares, corresponding to 3.61% of the share capital. The total number of shares in the company is 8,942,838 including treasury shares.

In accordance with the Regulation (EU) No. 596/2014, transactions related to the share buy-back programme are presented in detailed form in the appendix attached to this company announcement.

 

Enquiries and further information: CEO Peter Røpke, tel +45 96 32 23 00 RTX’s homepage: www.rtx.dk

 

Attachment

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Understanding Rollins' Current Market Position and Outlook

Updated Category News Views 226

Analyzing Rollins Inc.'s Stock Performance As we look at the current performance of Rollins Inc. (NYSE: ROL), the shares are trading around $55.73, reflecting a decrease of 1.24% in the recent session. While the stock has dipped by 3.81% over the past month, it has impressively increased by 10.91% year-over-year. This presents a curious juxtaposition of short-term...

Continue Reading
Silver One Reports Major Mineral Resource Estimate for Candelaria

Updated Category News Views 199

Candelaria Project Mineral Resource Estimate Silver One Resources Inc. (OTCQX: SLVRF) has made a significant announcement regarding the completion of a mineral resource estimate for the Candelaria Project. This estimate is prepared in accordance with the National Instrument 43-101, ensuring that the resources are assessed with high standards of transparency and accuracy....

Continue Reading
Investors Alert: Zynex (ZYXI) Faces Serious Legal Scrutiny

Updated Category News Views 197

Legal Investigation into Zynex, Inc. The Law Offices of Frank R. Cruz have announced a crucial investigation regarding Zynex, Inc. (ZYXI) focused on potential violations of federal securities laws. This investigation comes as a response to significant concerns raised about the company's recent financial disclosures and their implications for investors. Understanding the...

Continue Reading
Understanding Rentokil Initial's Stock Valuation Insights

Updated Category News Views 100

Assessing Rentokil Initial's Stock Performance In the current trading session, Rentokil Initial Inc. (NYSE: RTO) shares are priced at $26.42, witnessing a notable increase of 1.46%. Over the past month, the stock has gained 1.40%, though it has faced a decline of 7.78% in the last year. This fluctuation raises questions among shareholders regarding its valuation, despite...

Continue Reading
Innovative Insights on Efzofitimod from aTyr Pharma's Recent Conference

Updated Category News Views 177

aTyr Pharma Highlights Efzofitimod at Key Conference At a significant scientific gathering, aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology firm known for its innovative therapeutic approaches, shared compelling data concerning efzofitimod. This presentation underlined important insights about the treatment of pulmonary sarcoidosis. The conference, which...

Continue Reading